Life Sciences Team Advises Hepion Pharmaceuticals in $58.5 Million Merger Agreement with Pharma Two B
Sheppard Mullin’s Life Sciences team is representing Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA), a clinical stage biopharmaceutical company that is developing a treatment for non-alcoholic steatohepatitis hepatocellular carcinoma and other chronic liver diseases, in its merger agreement with Pharma Two B Ltd., a late-clinical stage private Israel-based company that is developing P2B001, an innovative combination product candidate in development for the treatment of Parkinson’s Disease. The merger is expected to close in the fourth quarter of 2024, subject to approval by Hepion’s stockholders, regulatory approval and other customary closing conditions.
The deal team advising Hepion is led by partner and Life Sciences team co-leader Jeffrey Fessler and partner Lindsay Ferguson, with invaluable assistance from partners Dmitriy Chelnitsky, Dominick DiSabatino, Eric Raphan and Niya Tang, special counsel Malika Levarlet and associates Keren Baruch, Brian Egan, Jared Fisher, Justine Lei, Seth Lemings, Audrey Mercer, Christina Nguyen and Lauren Watson.
Click here to read the press release.